Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kalaris Therapeutics Q2 EPS $(0.61) Misses $(0.52) Estimate

Author: Benzinga Newsdesk | August 13, 2025 07:06am
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 85.68 percent increase over losses of $(4.26) per share from the same period last year.

Posted In: KLRS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist